SCHEMBL1017466

SCHEMBL1017466

CC1CCCC2CN(C(=O)CN3CCc4nc(Cl)ccc4C3)CCN12

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.34
GAA P10253 2/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
CHRM2 P08172 2/20 0.33
CHRM4 P08173 2/20 0.33
CHRM1 P11229 2/20 0.33
PDCD1 Q15116 6/20 0.33
CD274 Q9NZQ7 6/20 0.33
HRH3 Q9Y5N1 1/20 0.33
CHRM3 P20309 1/20 0.33
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
HSD17B10 Q99714 2/20 0.32
PKM P14618 1/20 0.32
S1PR1 P21453 1/20 0.32
MMP2 P08253 1/20 0.31
CXCR3 P49682 1/20 0.31
TP53 P04637 1/20 0.31
PRMT5 O14744 1/20 0.31
WDR77 Q9BQA1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12707139 1.00 ALDH1A1 (0.34) ALDH1A1GAASMN1; SMN2CHRM2CHRM4
SCHEMBL1017308 0.84 CHRM2 (0.34) ALDH1A1GAASMN1; SMN2CHRM2CHRM4
SCHEMBL1018562 0.84 ADRA1A (0.36) ALDH1A1GAASMN1; SMN2CHRM2CHRM4
SCHEMBL12707147 0.84 CHRM2 (0.34) ALDH1A1GAASMN1; SMN2CHRM2CHRM4
SCHEMBL12707157 0.84 ADRA1A (0.36) ALDH1A1GAASMN1; SMN2CHRM2CHRM4
SCHEMBL1016304 0.83 HRH3 (0.43) ALDH1A1GAAHRH3HSD17B10PKM
SCHEMBL1019918 0.83 ADRA1A (0.36) ALDH1A1GAASMN1; SMN2PDCD1CD274
SCHEMBL1013680 0.83 ALDH1A1 (0.39) ALDH1A1GAANPC1RAB9AHSD17B10
SCHEMBL12707155 0.83 ALDH1A1 (0.39) ALDH1A1GAANPC1RAB9AHSD17B10
SCHEMBL12707159 0.83 ADRA1A (0.36) ALDH1A1GAASMN1; SMN2PDCD1CD274

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES LIGAND PHARMACEUTICALS, INC. (US) 2011-04-07 US disclosed
EP-1998620-B1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES NEUROGEN CORP (US) 2011-01-12 EP disclosed
US-7795262-B2 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION (US) 2010-09-14 US disclosed
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues NEUROGEN CORPORATION 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232591-A1 Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues HRH3, HRH4, HRH1 ALDH1A1 1229/4885GAA 2016/4885SMN1; SMN2 1615/4885
US-20110082130-A1 PIPERAZINYL OXOALKYL TETRAHYDROISOQUINOLINES AND RELATED ANALOGUES HRH3, HRH4, HRH1 ALDH1A1 1229/4885GAA 2016/4885SMN1; SMN2 1615/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.